Omega-3 correlation goes from non-significant to significant…

Annals fatty acid-coronary disease article gets corrected but not retracted

By Stephen DANIELLS

- Last updated on GMT

Annals fatty acid-coronary disease article gets corrected but not retracted
The authors of last week’s systematic review and meta-analysis in the Annals of Internal Medicine have issued a correction that changes the correlation of omega-3s to the relative risk for coronary outcomes from non-significant to significant.

As reported last week by NutraIngredients-USA​, an international team of scientists report that the evidence is inconclusive to encourage high consumption of omega-3s or omega-6s, and for guidelines to encourage lower consumption of saturated fats

The conclusions flew in the face of nutritional guidelines, which generally encourage low consumption of saturated fats, and high consumption of omega-3 polyunsaturated fatty acids.

While the mainstream media reported on the paper’s conclusions, the subsequent corrections have been largely ignored by that same media, according to the Global Organization for EPA and DHA Omega-3s (GOED).

The paper has received criticism from leading nutritionists, and some of the authors themselves have expressed disappointment with some of the conclusions.

Professor Walter Willett from the Harvard School of Public Health told Science Insider​: "They have done a huge amount of damage. I think a retraction with similar press promotion should be considered."

The authors have rejected calls for the paper to be retracted, but have issued a correction. 

Related news

Related products

show more

Gemini Pharmaceuticals Quality Partnership Program

Gemini Pharmaceuticals Quality Partnership Program

Gemini Pharmaceuticals | 09-Oct-2017 | Technical / White Paper

A Brand Owner/Own Label Distributor is 100% responsible for the quality of their products - not the Contract Manufacturing Organization. This is exactly...

Resveratrol – Revitalizing Cognitive Function

Resveratrol – Revitalizing Cognitive Function

Evolva | 29-Sep-2017 | Technical / White Paper

Cognitive decline is fast becoming the biggest concern of the 65+ population. A population which is set to reach 1.1 billion by 2030*.  · 80% of 60+ take...

NattoPharma

12 Reasons MenaQ7® is the Superior Vitamin K2

NattoPharma USA, Inc. | 11-Sep-2017 | Data Sheet

Vitamin K2 as MK-7 supplements are truly changing the face of global health, benefiting old and young alike. We know this because NattoPharma has single-handedly...

Related suppliers

Follow us

Products

View more

Webinars